Join the Oncology Voice Network. Join for Free
A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation
Biosimilars interchangeability extrapolation immunogenicity

A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation


Share This Article


Summary

  • Biologic agents have significantly improved the management of serious health conditions over the last two decades, offering better treatment outcomes and quality of life compared to traditional chemotherapy.
  • The cost of biologic drugs is high, leading to increased healthcare expenses. This mirrors the previous situation with branded chemical drugs, which was alleviated by introducing generics.
  • As many biologics are reaching the end of their patent exclusivity, there is potential for biosimilars to enter the market and reduce costs through increased competition.
  • However, market penetration of biosimilars is not guaranteed. Stakeholders need to have trust in biosimilars and their FDA-approved studies to incorporate them into practice.
  • Disseminating scientific and emerging evidence on biosimilars is crucial to help stakeholders make informed decisions and benefit from expanded treatment options.
  • The paper discusses the development and approval process of biosimilars, as well as challenges in their market implementation.

The simplest forms of biologic drugs entered the U.S. market in the 1970s and primarily consisted of blood products and vaccines. The rise of cloning and gene expression technology enabled biosynthesis of genetically modified organisms, which allowed the production of increasingly complex biologic molecules, including Genentech’s recombinant human insulin in 1982, the first FDA-approved monoclonal antibody and the entry of recombinant monoclonal antibodies in cancer treatment in 1997. Biologics, also known as therapeutic proteins, are medications produced in a laboratory to mimic natural proteins. This biologics mimic or antagonize a natural proteins function. Since then, biologics have revolutionized the treatment of serious medical conditions in the U.S. However, the high cost associated with biologic therapies along with increasing biologic utilization over the years have led to sharp increases in the overall healthcare cost curve. Table 1 provides a list of contributing factors as it relates to the increase of biologics utilization.  

Click for Source Download PDF version
Biosimilars, interchangeability, extrapolation, immunogenicity

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Evaluating External Validity of Oncology Biosimilar Safety Studies
OVN Avatar Gregory S. Calip, PharmD, MPH, PhD, Ivy P. Altomare, MD, Jenny S. Guadamuz, MSPH, PhD

Evaluating External Validity of Oncology Biosimilar Safety Studies

Article
Medical Oncologists’ Knowledge and Perspectives on the Use of Biosimilars in the United States
OVN Avatar John Devin Peipert, PhD, Karen Kaiser, PhD, Sheetal Kircher, MD, George J. Greene, PhD, Sara Shaunfield, PhD, Katherina Hauner, PhD, David Cella, PhD, and Daniel K. Mroczek, PhD

Medical Oncologists’ Knowledge and Perspectives on the Use of Biosimilars in the United States

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN